Argenx to Acquire Forte Biosciences for $2.2 Billion in Cash
Jul 27, 2026, 1:09 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The cash deal with an 86% premium versus recent VWAP creates an immediate, material value realization for Forte holders and signals high appetite for CD122 biology within immunology peers, which can lift sentiment for related names and general takeout activity in the space. For FBRX, this may reprice takeout premium expectations and validate downstream value if FB102 is viewed as a meaningful CD122 asset in a strategic buyer's pipeline.
AI summary
What happened, with direct paths to the underlying reporting
Argenx and Forte Biosciences announced a definitive agreement for Argenx to acquire Forte in a cash tender at $77 per Forte share, valuing Forte at about $2.2 billion with closing expected in Q3 2026. FB102, Forte’s anti-CD122 program, has Phase 1b data in vitiligo and celiac disease, supporting a pipeline-in-a-product potential. The deal broadens Argenx’s immunology platform and could accelerate FB102 development across autoimmune indications.
Argenx to acquire Forte Biosciences for $77/share cash (~$2.2B).
FB102 Phase 1b data validate CD122 biology; pipeline-in-a-product potential.
Acquisition adds a differentiated anti-CD122 approach to argenx's portfolio.
Close targeted for Q3 2026; funded entirely from Forte's cash; HSR awaited.
Forte management highlights FB102's potential across vitiligo, celiac, and alopecia areata.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Forte Biosciences reported positive Phase 1b results for FB102 in facial vitiligo, showing a 21.7% placebo-adjusted FVASI improvement at week 24 and an early signal by day 64. Mor…
